Apnimed, Inc. (APMD)
27.33
-1.67
(-5.76%)
USD |
NASDAQ |
Sep 21, 09:56
Apnimed Enterprise Value : 1.361B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 1.361B |
| September 17, 2026 | 1.324B |
| September 16, 2026 | 1.281B |
| September 15, 2026 | 1.218B |
| September 14, 2026 | 1.217B |
| September 11, 2026 | 1.245B |
| September 10, 2026 | 1.269B |
| September 09, 2026 | 1.322B |
| September 08, 2026 | 1.352B |
| September 04, 2026 | 1.296B |
| September 03, 2026 | 1.311B |
| September 02, 2026 | 1.312B |
| September 01, 2026 | 1.271B |
| August 31, 2026 | 1.246B |
| August 28, 2026 | 1.390B |
| August 27, 2026 | 1.349B |
| August 26, 2026 | 1.385B |
| August 25, 2026 | 1.293B |
| Date | Value |
|---|---|
| August 24, 2026 | 1.220B |
| August 21, 2026 | 1.320B |
| August 20, 2026 | 1.342B |
| August 19, 2026 | 1.487B |
| August 18, 2026 | 1.478B |
| August 17, 2026 | 1.509B |
| August 14, 2026 | 1.475B |
| August 13, 2026 | 1.352B |
| August 12, 2026 | 1.263B |
| August 11, 2026 | 1.189B |
| August 10, 2026 | 1.317B |
| August 07, 2026 | 1.278B |
| August 06, 2026 | 1.314B |
| August 05, 2026 | 1.257B |
| August 04, 2026 | 1.224B |
| August 03, 2026 | 1.194B |
| July 31, 2026 | 1.194B |
| July 30, 2026 | 819.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| IGC Pharma, Inc. | 29.92M |
| Cocrystal Pharma, Inc. | 15.78M |
| CNBX Pharmaceuticals, Inc. | 1.313M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -18.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 126.11M |
| Revenue (Quarterly) | 12.08M |
| Total Expenses (Quarterly) | -114.03M |
| EPS Diluted (Quarterly) | 3.025 |
| Gross Profit Margin (Quarterly) | 89.98% |
| Earnings Yield | 8.55% |
| Operating Earnings Yield | 2.09% |
| Normalized Earnings Yield | 8.666 |